Taiwanese startup Aulea Medical participated in the "IP2 Scale Out Program," a project jointly organized by i2i and the U.S. startup accelerator EntreCamp. During the investment pitch event in Manhattan on June 21, founder George Hsu presented the company’s innovative products and technologies, successfully capturing the attention of the East Coast investment community and advancing their fundraising and market entry plans.
Aulea Medical’s core product, the Single Use All-in-One Endoscopic Resection Device "Veloxion Resectoscope," has undergone eight years of development by a professional team and boasts multiple patents and FDA certifications, demonstrating significant growth potential.
(George Hsu, founder and CEO of Aulea Medical, showcased the developed innovative medical device at the investment demo day.)
Aulea Medical’s core product, the Single Use All-in-One Endoscopic Resection Device "Veloxion Resectoscope," has been meticulously developed over eight years. It holds a comprehensive set of patents, four FDA 510(k) approvals, and two valid insurance reimbursement codes. Founder George Hsu emphasized that the product has high commercialization potential, with the ability to quickly enter production and a stable supply chain and existing customer base.
George Hsu stated that the primary goal of participating in IP2 Scale Out Program was to gain more exposure and commercial network support while conducting Series A fundraising. Additionally, New York is a market that Aulea had previously seldom explored. Through the Program, the company could gain deeper insights into the local market and interact with industry experts and physicians, obtaining valuable feedback. "The mentors from the Program and the industry professionals we visited provided tremendous help. Building these connections is crucial for expanding our business footprint."
(Hsu highlighted the market potential of the company's product, attracting significant interest from potential investors.)
Commentaires